In the evolving field of chemical biology and targeted protein degradation, the study of vhl binding peptide structures has become a cornerstone for researchers. As someone deeply interested in the mechanics of molecular recognition, I have spent significant time reviewing how Download scientific diagram | Chemical structures of VHL ligands and their binding affinities to VHL protein and the design and optimization of AR PROTACs. these sequences interact with the von Hippel-Lindau (VHL) protein VHL Ligand 1 HCl salt . Understanding the intricacies of these interactions is essential, particularly when one considers that the VHL protein domain, specifically the β domain, serves as a critical docking site for hydroxylated prolines.
The Mechanism of VHL Interaction
When we look at how polypeptides are able to bind to VHL, we are essentially observing a highly specific molecular "handshake." The core of this interaction relies on the trans-epimer of hydroxyproline. It is a well-documented observation in structural biology that the trans-epimer is an absolute requirement for binding; conversely, the cis-epimer effectively abrogates this process.
In my exploration of these compounds, I have noted that VHL is one of the most widely utilized E3 ligases, alongside Cereblon (CRBN). Researchers often utilize specific ligands to bridge the gap between a protein of interest (POI) and the E3 ligase machinery. A key insight here is that PROTACs are tripartite molecules consisting of a ligand for the POI, a linker, and a VHL recruiter.
Structural Insights and Peptide Utility
The versatility of the peptide modality cannot be overstated. Unlike traditional small molecules, Peptide PROTACs—such as the potent FPP29, which acts as a peptide-based FOXM1 PROTAC degrader—offer unique advantages, including structural flexibility and potential for multi-targeting.
However, it is important to maintain a realistic perspective on the landscape of this technology. Currently, PROTAC can only hijack less than 1% of E3 ligases in the body, including VHL, IAP, Keap1, and RNF4. This limitation drives the intense interest in optimizing VHL binding affinity. For instance, VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a Kd value in the range of 80 to 90 nM, illustrating the precision required in these designs.
Practical Considerations in Research
When analyzing the chemical structures of VHL ligands and their binding affinities, one must account for the physical state of the molecules. Studies have shown that there is more disorder in the peptide-like VHL binding region, and the linker component is often highly disordered, which can influence the stability of the ternary complex.
For those involved in experimental wo by Y Zhu · 2025 · Cited by 20 — Peptide PROTACs have advantages such as multitargeting, biodegradability, low toxicity, and flexibility in structural design. rkflows, reagents suc Review on VHL ligands – Ciulli Laboratory h as VHL Ligand 1 HCl salt serve as standard benchmarks. When a bifunctional molecule binds the POI at one end while simultaneously recruiting the E3 ligase, it forms a ternary complex that facilitates the catalytic degradation of th Targeted protein degradation e target. A prime example of this is seen in GMB-475, which is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1.
Summary of Observations
My experience with these materials highlights a few critical takeaways for any enthusiast or by CJ Diehl · 2022 · Cited by 256 — We cover the structure-based design of VHL ligands, their application as inhibitors in their own right, and their implementation into rationally designed, researcher:
* Specificity: The requirement for a specific hydroxyproline configuration is non-negotiable for effective VHL binding.
* Design Complexity: Whether using a small molecule like VH032 or a more complex peptide-based degrader, the linker length and rigidity are paramount to successful ternary complex formation.
* Evolving Landscape: While VHL remains a primary target, the field is constantly searching for novel E3 ligases to expand the current 1% threshold of hijackable proteins.
By focusing on the structural biology of these ligands, we gain a better appreciation for how these tools can be applied in advan The peptide PROTAC modality: a novel strategy for targeted ced research. It is a fascinating intersection of chemistry and biology that continues to push the boundaries of molecular design.